Kick It Old School - Creating Reports with the DATA _NULL_ Step

Size: px
Start display at page:

Download "Kick It Old School - Creating Reports with the DATA _NULL_ Step"

Transcription

1 Kick It Old School - Creating Reports with the DATA _NULL_ Step Sai Ma, PharmaNet/i3, Toronto, Ontario Canada Suwen Li, Everest Clinical Research Services Inc., Markham, Ontario Canada Minlan Li, Everest Clinical Research Services Inc., Markham, Ontario Canada ABSTRACT The powerful PROC REPORT can handle most of the clinical trial data reporting tasks. But when the report needs to be customized to meet special requirements, PROC REPORT can sometimes be awkward. This is where the DATA _NULL_ step comes to the rescue. It is old school. However, it allows you to have complete control in customizing your reports. This paper illustrates when and how to generate study reports using DATA _NULL_ step by two examples. KEY WORDS DATA _NULL_, AE, Study Comments, PROC REPORT INTRODUCTION PROC REPORT is a dominating reporting tool to tabulate, display, and in some cases, analyze clinical data. It is powerful, flexible and easy to use. But sometimes, we just wish it could do a little bit more. This extra bit can often make us scratch our heads for days. DATA _NULL_ step can be a practical alternative in a situation like this. Using DATA _NULL_ step to generate a report is like painting on a blank canvas. You can almost display anything anywhere on the report. It also covers some blind spots of PROC REPORT so that the report-generating task is simplified and handled more efficiently. Two examples follow. The first example outlines how to make one SOC (system organ class) group of AE (adverse event) terms continuously flow to the next page when multiple columns need to spread over more than one page, and the second one elaborates on how to display long study comments in subject listings. Both examples show why DATA _NULL_ step is preferred over PROC REPORT under certain circumstances. The main focus of this paper is not to give a detailed tutorial on the usage of DATA _NULL_ step; rather, it is to show when and how DATA _NULL_ step can be used as a supplement to PROC REPORT. EXAMPLE 1: AE TABLE WITH THE SAME SOC TERMS CARRIED TO THE NEXT PAGE FOR ALL TREATMENT GROUPS SPLIT OVER TWO PAGES The table display requirements are as such: 1) The wrapped SOC term should be properly indented to enhance readability. For example, Neoplasms benign, malignant and unspecified (incl cysts and 4 ( 4.6) 4 ( 2.5) polyps) should appear: Neoplasms benign, malignant and unspecified (incl cysts and 4 ( 4.6) 4 ( 2.5) polyps) 2) If all the AE preferred terms under a SOC term cannot be printed on the same page, the SOC term should be displayed at the top of the following page with text "(CONT.)" attached to indicate continuation. For example, Infections and infestations 4 ( 5.6) 2 ( 2.3) Upper respiratory tract infection 2 ( 2.8) 1 ( 1.1) Urinary tract infection 1 ( 1.4) 1 ( 1.1) with top of the next page: Infections and infestations (CONT.) Influenza 1 ( 1.4) 0 3) To present the data in the most sensible form for comparison given the page size limitation, we need to split the desired treatment groups over 2 pages: Treatment group A, B, and C on the first page and D and E on the second. Applying the indentation requirement is not substantially different between PROC REPORT and DATA _NULL_ step. With proper data manipulation, both approaches can achieve this. It is the second and third requirements that deserve 1

2 some thinking. By PROC REPORT, it does not seem feasible to get around the programming complexity of manually calculating the total number of terms a page can contain. The calculation difficulty can easily be escalated when considering indentation and counts for the insertion of blank lines after each group. If the total SOC groups, or the total AE terms, per page are simply set to a fixed number to ensure same group of preferred terms do not cross pages, the whole report loses its flexibility in displaying data and the output could become aesthetically unappealing. DATA _NULL_ step can circumvent this issue well. As a first step, we wrap the AE term (both SOC and preferred terms). This is accomplished by using an extra DATA step. Assuming the default delimiter that separates each individual word in an AE term is a space (" "), then we must consider the following three cases: 1) The term breaks in the middle of a word. e.g., xxxx xxxxx xxxxx or xxxxxxx xx xxxx 2) The term breaks in the middle of a word, but the first half of the term is in one piece (no word delimiters; namely, a very long word). e.g., xxxxxxxxxx xxxx 3) The term breaks between two words. e.g., xxxxxxxxxx xxxx or xxxxxxxxx xxxx In all three scenarios, the piece that is cut from the original AE term will be saved separately and the remaining piece will continue to loop this process until the whole term is exhausted. Further, in the second scenario, a bar ("-") will be inserted at the end of the cut part to indicate word truncation. A counter variable (WRAPLINE) can tell how many pieces the original AE term is cut into. Sample data on wrapped AE terms can be found in Output 1. After this is done, DATA _NULL_ step can take care of the rest. Line size, page size, variable of number of lines processed and the variable of number of remaining lines are all defined in FILE statement. The PRINT option makes sure the output file contains carriage control characters. data _null_; set nesug12 end=lastrec; file print ls=132 notitles line=lineno ll=lineleft ps=52; Then we need a variable to flag new page (NEWPAGE) and a variable to keep track of the page number (PAGENO). They are both updated under the HEADER statement label which is linked at the top of each page. The _PAGE_ modifier creates a page break at the beginning of each page. When the DATA step hits the dataset boundary or the beginning of the spaces saved for footnotes, statements under label FOOTER will be linked. The contents of the predefined footnote macro variables (&&FFOOT&J) will be loaded in the report. As a syntax note, we need two RETURN statements for each statement label to prevent the statements being executed with each iteration of the DATA step. if lineno eq 1 then link header; if lastrec or lineleft le &footnum+1 then link footer; header: put _page_; pageno+1; newpage=1; footer: 132*'_' ; %do j=1 %to &footnum; &&ffoot&j; % To address the second table display requirement, we should carefully consider the circumstances that table headers and footnotes need to be inserted. Apart from the beginning and the bottom part of the page, when a wrapped AE term (SOC term or preferred term) requires more lines than what remains on the page (tested by comparing the values of variable 2

3 LINELEFT and macro variable FOOTNUM), then both HEADER and FOOTER labels should be linked. Also, if a page break is inserted in the middle of the same group of preferred terms, the corresponding SOC term will be carried forward to the following page and the new page flag is reset to zero. Variable CONT is used to flag the AE term after which we need to break the SOC group to flow to the next page and insert the text "(CONT.)". This is also necessary in order to meet the third requirement. All the AE terms will populate the report through the adjustment of the column pointer control (@). The exact number of spaces to be indented depends on the output column width and the study report requirements. if not first.soc_term and newpage eq 1 then do; soc_term "(CONT.)"; cont=1; newpage=0; The variable PAGENO generated by DATA _NULL_ step counts the page numbers for us. This is a very useful feature not only to allow treatment groups to flow over pages (i.e., the third requirement), but to support applications like generating dynamic report footnotes (e.g., only on first/alternate/selected pages). To get this key information, all we need is to run data through the DATA _NULL_ step one extra time before we use the DATA _NULL_ step to generate the final output. The output dataset from the first pass of DATA _NULL_ step (FINAL) will be needed, hence saved, to determine the desired page number, and the actual output can then be suppressed by ODS statements. With the page number in place, we are now ready to split the data from each page into two parts: the first part is for the first three treatment groups (Treatments A, B, and C), and the second part is for the remaining two groups (Treatments D and E). data final; set nesug12 end=lastrec; file print ls=132 notitles line=lineno ll=lineleft ps=52; data final; set final (rename=(pageno=pagegrp) in=aaa drop=treat_d: treat_e:) final (rename=(pageno=pagegrp) in=bbb drop=treat_a: treat_b: treat_c:) ; if aaa then pagesub=1; else if bbb then pagesub=2; proc sort data=final; by pagesub soc_term pt_term wrapline; The new variables CONTSEQ1, CONTSEQ2, PAGESUB and PRESUB are used together to flag the page breaks and to insert the headers and footnotes. Treatments will be displayed within each PAGESUB group (A, B, and C if PAGESUB is 1; D and E if PAGESUB is 2). All other steps follow what the first DATA _NULL_ step defines. data final; set final; by pagegrp pagesub soc_term pt_term wrapline; if first.soc_term and missing(cont) then contseq1+1; if first.soc_term then contseq2+1; presub=lag(pagesub); data _null_; set final end=lastrec; file print ls=132 notitles line=lineno ll=lineleft ps=52; by contseq1 contseq2 soc_term pt_term wrapline; if lineno eq 1 then link header; if not missing(presub) and (pagesub ne presub) then do; link footer; link header; if not first.contseq1 and newpage eq 1 then soc_term "(CONT.)"; newpage=0; if pagesub eq 1 then do; else if pagesub eq 2 then do; 3

4 if lastrec then link footer; header: footer: Although PROC REPORT can handle a situation where multiple treatment groups must flow over many pages (by suppressing the WRAP option in the PROC REPORT statement and specifying ID option in the DEFINE statement for the repeating variables), the insertion of page continuation text "XXXX XXX (CONT.)" still requires some additional calculation on the report page capacity. As discussed above, for tables with standard outputs (i.e., all treatment groups can be displayed within the same page), DATA _NULL_ step bypasses this need completely, whereas for tables with special output requirements as in the example above, DATA _NULL_ step can automatically generate the page numbers that takes all other requirements into consideration (wrapping long AE terms and breaking pages under the same SOC term). This makes DATA _NULL_ step a very appealing and effective approach for this type of application. Sample data is listed below in Output 1. Selected outputs are attached in the appendix (Output 5). CONTSEQ1 CONTSEQ2 PAGEGRP PAGESUB PRESUB CONT SOC_TERM Psychiatric disorders Psychiatric disorders Psychiatric disorders Psychiatric disorders Psychiatric disorders Psychiatric disorders Psychiatric disorders Psychiatric disorders Psychiatric disorders Psychiatric disorders SOC_NEW PT_TERM PT_NEW WRAPLINE Psychiatric disorders 1 Psychiatric disorders Abnormal dreams Abnormal dreams 1 Psychiatric disorders Anxiety Anxiety 1 Psychiatric disorders 1 Psychiatric disorders Abnormal dreams Abnormal dreams 1 Psychiatric disorders Anxiety Anxiety 1 Psychiatric disorders Bruxism Bruxism 1 Psychiatric disorders Restlessness Restlessness 1 Respiratory, thoracic and 1 mediastinal disorders 2 Respiratory, thoracic and mediastinal disorders Paranasal sinus hypersecretion Paranasal sinus 1 Respiratory, thoracic and mediastinal disorders Paranasal sinus hypersecretion hypersecretion 2 Respiratory, thoracic and mediastinal disorders Rhinorrhoea Rhinorrhoea 1 Respiratory, thoracic and mediastinal disorders Sinus congestion Sinus congestion 1 Psychiatric disorders Bruxism Bruxism 1 Psychiatric disorders Restlessness Restlessness 1 Respiratory, thoracic and 1 mediastinal disorders 2 Respiratory, thoracic and mediastinal disorders Paranasal sinus hypersecretion Paranasal sinus 1 Respiratory, thoracic and mediastinal disorders Paranasal sinus hypersecretion hypersecretion 2 Respiratory, thoracic and mediastinal disorders Rhinorrhoea Rhinorrhoea 1 Respiratory, thoracic and mediastinal disorders Sinus congestion Sinus congestion 1 Output 1. Sample Data - Page Break Flags and Wrapped AE Terms 4

5 EXAMPLE 2: LISTING WITH EXCESSIVELY LONG COMMENTS Comment variables are typically lengthy (up to 200 characters) in the context of clinical trial studies. For certain data panels, for example, ECG, Questionnaire, or Overall Study Comments, there can be more than one comment variable collected. A typical method to display all the comments in the relevant subject data listing is to stack them vertically, and to squeeze other fields into the report as much as possible to make room for this column. However, such a listing is prone to have a disproportionally slim comment field. Our goal when incorporating study comments within subject data listings is to ensure that the reviewer sees complete subject information without having to flip pages, as presented in Display 1. AABBCC PHARMACEUTICALS COMPOUND ## Protocol XXXXXX123 Page xxx of yyy Listing - Subject Disposition and Evaluability Site # (Inv. Name) / Subject Treatment Date Disposition Date (yyyy-mm-dd) Last Duration (days) Reason for Treatment ITT EPP # Group Consented Dose Discontinued (yyyy-mm-dd) Study Last (tabs) Study Treatment Completed/ Dose Discontinued XXX (XXXXXXXXXXXX) 001 Placebo XXXX-XX-XX Completed/ XXXX-XX-XX XXXX-XX-XX X XXX XXX Completed/ Yes/ Yes/ Discontinued study/ Withdrawal of consent/ No No Adverse Events/ Comment: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX Display 1. Listing Shell To this end, we first concatenate all the original comment variables into a new variable (CMNT). Similar to what is done in Example 1, we then decompose this new comment variable into pieces and assign them to individual variables (CMNT1 - CMNT4). The variable length for each piece can be as long as the full line size of the report. However, a reasonably large number is usually sufficient (e.g., 100) for a better layout. Once the length is decided, the actual "cutting" part is fairly straightforward. j=0; i=100; do while (compress(cmnt) ne ''); temp=substr(cmnt,1,i); cutoff=substr(temp,i,1); i=i-1; do while (cutoff ne ' '); cutoff=substr(temp,i,1); i=i-1; j=j+1; if j=1 then cmnt1=substr(temp,1,i); else if j=2 then cmnt2=substr(temp,1,i); else if j=3 then cmnt3=substr(temp,1,i); else if j=4 then cmnt4=substr(temp,1,i); cmnt=substr(cmnt,i+2); Output 2 has the sample data. cmnt1 Comment: SUBJECT INDEPENDENTLY D/C'ED STUDY MED (PRECIPITATED BY AES) 99XXX2099 AND MADE SITE AWARE cmnt2 OF THIS ON 99XXX99. SHE WAS SCHEDULED FOR HER TERM VISIT ON 99XXX99 BUT DID NOT KEEP THAT APPT. cmnt3 AFTER NUMEROUS ATTEMPTS TO CONTACT HER (PHONE CALLS AND CERT. MAIL) SHE WAS, ON 99XXX2099 cmnt4 5

6 CONSIDERED LOST TO FOLLOW-UP SECONDARY TO "NO SHOWS" AT NUMEROUS TERM. APPTS. Output 2. Sample Data - Comment Variable Decomposition BY PROC REPORT The first attempt to generate the listing is handled by PROC REPORT. Four comment variables are stacked together (CMNTV) for the use of COMPUTE block within PROC REPORT, as shown in Output 3. compute after cmntv; cmntv $100.; endcomp; subnum cmntv 777 Comment: SUBJECT INDEPENDENTLY D/C'ED STUDY MED (PRECIPITATED BY AES) 99XXX2099 AND MADE SITE AWARE 777 OF THIS ON 99XXX99. SHE WAS SCHEDULED FOR HER TERM VISIT ON 99XXX99 BUT DID NOT KEEP THAT APPT. 777 AFTER NUMEROUS ATTEMPTS TO CONTACT HER (PHONE CALLS AND CERT. MAIL) SHE WAS, ON 99XXX CONSIDERED LOST TO FOLLOW-UP SECONDARY TO "NO SHOWS" AT NUMEROUS TERM. APPTS. Output 3. Sample Data - Prepared for PROC REPORT The output created by PROC REPORT looks fine for short records (i.e., only CMNT1 is non-missing), but is problematic for longer records. The data are not grouped properly by the COMPUTE block. Blank lines are automatically inserted after the comment text. Furthermore, when the page break happens to lie among multiple comment lines for the same subject, subject data are not the first row at the top of next page as expected. Instead, they are embedded between comments (Output 4). All of these issues call for an alternative - DATA _NULL_ step. AABBCC PHARMACEUTICALS COMPOUND ## Protocol XXXXXX123 Page xx1 of yyy Listing - Subject Disposition and Evaluability Site # (Inv. Name) / Subject Treatment Date Disposition Date (yyyy-mm-dd) Last Duration (days) Reason for Treatment ITT EPP # Group Consented Dose Discontinued (yyyy-mm-dd) Study Last (tabs) Study Treatment Completed/ Dose Discontinued 999 (Cccccc C. Ccccccc, M.D.) 555 Placebo Discontinued study Other: lost to follow-up Yes No Comment: SUBJECT NEVER CAME IN FOR WK 34 CLINIC VISIT, SEVERAL ATTEMPTS WERE MADE TO CONTACT SUBJECT, LAST CONFIRMED DOSE SUBJECT TOOK WAS 9/99/2099 AND WAS TABS. 777 Placebo Discontinued study Investigator's decision Yes No Comment: SUBJECT INDEPENDENTLY D/C'ED STUDY MED (PRECIPITATED BY AES) 99XXX2099 AND MADE SITE AWARE 6

7 AABBCC PHARMACEUTICALS COMPOUND ## Protocol XXXXXX123 Page xx2 of yyy Listing - Subject Disposition and Evaluability Site # (Inv. Name) / Subject Treatment Date Disposition Date (yyyy-mm-dd) Last Duration (days) Reason for Treatment ITT EPP # Group Consented Dose Discontinued (yyyy-mm-dd) Study Last (tabs) Study Treatment Completed/ Dose Discontinued OF THIS ON 99XXX99. SHE WAS SCHEDULED FOR HER TERM VISIT ON 99XXX99 BUT DID NOT KEEP THAT APPT. 777 Placebo Discontinued study Investigator's decision Yes No AFTER NUMEROUS ATTEMPTS TO CONTACT HER (PHONE CALLS AND CERT. MAIL) SHE WAS, ON 99XXX99 CONSIDERED LOST TO FOLLOW-UP SECONDARY TO "NO SHOWS" AT NUMEROUS TERM. APPTS. 888 Treatment Completed Completed Yes Yes Output 4. Sample Output - Generated by PROC REPORT BY DATA _NULL_ STEP Because the comment variables have already been reconciled into the ready-to-output form, DATA _NULL_ step can just write the data out to the report. Everything is controlled by querying the variable containing the number of remaining lines (REMAIN). Actions are taken when the number of remaining lines drops below the threshold in different testing situations. Again, as the following program shows, no complex calculation is needed and everything flows logically to create the final output (Output 6, Appendix). data _null_; set pharma12; by inv subnum; file print footnote header=newpage linesleft=remain; if first.inv then do; if remain eq 2 and missing(cmnt1) or remain lt 5 and not missing(cmnt1) or remain lt 6 and not missing(cmnt2) or remain lt 7 and not missing(cmnt3) or remain lt 8 and not missing(cmnt4) then put _page_ / inv; else put / inv; if not missing(cmnt4) then do; if remain lt 6 then put _page_ / &listvar cmnt1 cmnt2 cmnt3 cmnt4; else put / &listvar cmnt1 cmnt2 cmnt3 cmnt4; else if not missing(cmnt3) then do; if remain lt 5 then put _page_ / &listvar cmnt1 cmnt2 cmnt3; else put / &listvar cmnt1 cmnt2 cmnt3; else if not missing(cmnt2) then do; if remain lt 4 then put _page_ / &listvar cmnt1 cmnt2; else put / &listvar cmnt1 cmnt2; else if not missing(cmnt1) then do; if remain lt 3 then put _page_ / &listvar cmnt1; else put / &listvar cmnt1; else if missing(cmnt1) then put / &listvar; newpage: put "%sysfunc(repeat(%str(_),132))" / "Site # (Inv. Name) /" // " Subject Treatment Date Disposition Date (yyyy-mm-dd)" " Last Duration (days) Reason for Treatment ITT EPP"/ 7

8 " # Group Consented " " Dose Discontinued"/ " (yyyy-mm-dd) Study Last" " (tabs) Study Treatment"/ " Completed/ Dose" " "/ " Discontinued"/ "%sysfunc(repeat(%str(_),132))"; if not first.inv then do; if first.subnum then put / inv '(CONT.)'; CONCLUSION DATA _NULL_ step is not out of the picture as a reporting tool, although people do tend to choose the more wellrounded PROC REPORT. It is still an ideal technique to consider for reports that have special requirements, or, are too complicated to be created by PROC REPORT. There are a number of other nice features that DATA _NULL_ step can offer when used to create study reports, for example, routing report output, executing special functions or call routines available within the DATA step, interacting with ODS, and creating flat files for other programs and databases [1]. Become familiar with the basic syntax and study some interesting examples, so that you can give DATA _NULL_ step a shot next time you struggle with a fancy-looking report. REFERENCES [1]. Bahler, Caroline; Brinsfield, Eric (2002), "Report Creation Using Data _NULL_", SUGI 27 Proceedings, April 14-17, 2002, Orlando, Florida. [2]. Carpenter, Arthur L., "Creating Customized Reports Using the DATA _NULL_ Step". ACKNOWLEDGMENTS The author wants to thank Beizhen Lei and Kathy Colucci for their invaluable comments on this paper. CONTACT INFORMATION Your comments and questions are valued and encouraged. Contact the author at: Name: Sai Ma Enterprise: PharmaNet/i3 City, State: Toronto, Ontario Canada Work Phone: (905) Fax: (905) sma@pharmanet-i3.com Web: SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. indicates USA registration. Other brand and product names are trademarks of their respective companies. 8

9 Page 1 APPENDIX Table: Incidence of Adverse Events by Treatment Group, System Organ Class, Preferred Term, and Severity System Organ Class/ Treatment A Treatment B Treatment C Preferred Term (N=XX) (N=XX) (N=XX) Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) Psychiatric disorders 5 (16.7) (7.4) (20.8) 0 0 Abnormal dreams 4 (13.3) (12.5) 0 0 Anxiety 3 (10.0) Page 2 Table: Incidence of Adverse Events by Treatment Group, System Organ Class, Preferred Term, and Severity System Organ Class/ Treatment D Treatment E Preferred Term (N=XX) (N=XX) Mild Moderate Severe Mild Moderate Severe n (%) n (%) n (%) n (%) n (%) n (%) Psychiatric disorders (40.0) 0 0 Abnormal dreams (23.3) 0 0 Anxiety (10.0) 0 0 Page 3 Table: Incidence of Adverse Events by Treatment Group, System Organ Class, Preferred Term, and Severity System Organ Class/ Treatment A Treatment B Treatment C Preferred Term (N=XX) (N=XX) (N=XX) Mild Moderate Severe Mild Moderate Severe Mild Moderate Severe n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) Psychiatric disorders (CONT.) Bruxism (4.2) 0 0 Restlessness (8.3) 0 0 Respiratory, thoracic and 1 (3.3) (7.4) (8.3) 0 0 mediastinal disorders Paranasal sinus (3.7) (4.2) 0 0 hypersecretion Page 4 Table: Incidence of Adverse Events by Treatment Group, System Organ Class, Preferred Term, and Severity System Organ Class/ Treatment D Treatment E Preferred Term (N=XX) (N=XX) Mild Moderate Severe Mild Moderate Severe n (%) n (%) n (%) n (%) n (%) n (%) Psychiatric disorders (CONT.) Bruxism (3.3) 0 0 Restlessness (6.7) 0 0 Respiratory, thoracic and (13.3) 0 0 mediastinal disorders Paranasal sinus (6.7) 0 0 hypersecretion Output 5. Final Output - Example 1 9

10 AABBCC PHARMACEUTICALS COMPOUND ## Protocol XXXXXX123 Page xx1 of yyy Listing - Subject Disposition and Evaluability Site # (Inv. Name) / Subject Treatment Date Disposition Date (yyyy-mm-dd) Last Duration (days) Reason for Treatment ITT EPP # Group Consented Dose Discontinued (yyyy-mm-dd) Study Last (tabs) Study Treatment Completed/ Dose Discontinued 999 (Cccccc C. Ccccccc, M.D.) 111 Placebo Discontinued study Adverse event Yes Yes 222 Treatment Completed Completed Yes Yes 333 Placebo Discontinued trt Other Yes No Comment: PATIENT WANTED TO DISCONTINUE TREATMENT BECAUSE SHE BELIEVED IT WASN'T BENEFICIAL TO HER. 444 Treatment Discontinued study Withdrawal of consent Yes No 555 Placebo Discontinued study Other: lost to follow-up Yes No Comment: SUBJECT NEVER CAME IN FOR WK 34 CLINIC VISIT, SEVERAL ATTEMPTS WERE MADE TO CONTACT SUBJECT, LAST CONFIRMED DOSE SUBJECT TOOK WAS 9/99/2099 AND WAS TABS. 666 Treatment Completed Completed Yes Yes 777 Placebo Discontinued study Investigator's decision Yes No Comment: SUBJECT INDEPENDENTLY D/C'ED STUDY MED (PRECIPITATED BY AES) 99XXX2099 AND MADE SITE AWARE OF THIS ON 99XXX99. SHE WAS SCHEDULED FOR HER TERM VISIT ON 99XXX99 BUT DID NOT KEEP THAT APPT. AFTER NUMEROUS ATTEMPTS TO CONTACT HER (PHONE CALLS AND CERT. MAIL) SHE WAS, ON 99XXX2099 CONSIDERED LOST TO FOLLOW-UP SECONDARY TO "NO SHOWS" AT NUMEROUS TERM. APPTS. Output 6. Final Output - Example 2 10

Generate Informative Clinical Laboratory Results Listing

Generate Informative Clinical Laboratory Results Listing PharmaSUG2011 - Paper PO02 Generate Informative Clinical Laboratory Results Listing Sai Ma, Everest Clinical Research Services Inc., Markham, Ontario Canada ABSTRACT Clinical laboratory results review

More information

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables

PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables PharmaSUG 2012 - Paper IB09 PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables Sneha Sarmukadam, Statistical Programmer, PharmaNet/i3, Pune, India Sandeep

More information

Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ

Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ ABSTRACT: If you use SAS Proc Report frequently, you will be familiar with the flow option. The flow option wraps

More information

MyDispense OTC exercise Guide

MyDispense OTC exercise Guide MyDispense OTC exercise Guide Version 5.0 Page 1 of 23 Page 2 of 23 Table of Contents What is MyDispense?... 4 Who is this guide for?... 4 How should I use this guide?... 4 OTC exercises explained... 4

More information

Pharmaceutical Applications

Pharmaceutical Applications Creating an Input Dataset to Produce Incidence and Exposure Adjusted Special Interest AE's Pushpa Saranadasa, Merck & Co., Inc. Abstract Most adverse event (AE) summary tables display the number of patients

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive

More information

Creating Multiple Cohorts Using the SAS DATA Step Jonathan Steinberg, Educational Testing Service, Princeton, NJ

Creating Multiple Cohorts Using the SAS DATA Step Jonathan Steinberg, Educational Testing Service, Princeton, NJ Creating Multiple Cohorts Using the SAS DATA Step Jonathan Steinberg, Educational Testing Service, Princeton, NJ ABSTRACT The challenge of creating multiple cohorts of people within a data set, based on

More information

1. Automatically create Flu Shot encounters in AHLTA in 2 mouse clicks. 2. Ensure accurate DX and CPT codes used for every encounter, every time.

1. Automatically create Flu Shot encounters in AHLTA in 2 mouse clicks. 2. Ensure accurate DX and CPT codes used for every encounter, every time. In clinics around the MHS, upwards of 70% of all flu shot workload credit is lost because the encounters are not documented within AHLTA. Let the Immunization KAT s PASBA approved coding engine do the

More information

OneTouch Reveal Web Application. User Manual for Healthcare Professionals Instructions for Use

OneTouch Reveal Web Application. User Manual for Healthcare Professionals Instructions for Use OneTouch Reveal Web Application User Manual for Healthcare Professionals Instructions for Use Contents 2 Contents Chapter 1: Introduction...4 Product Overview...4 Intended Use...4 System Requirements...

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Technology Appraisals. Patient Access Scheme Submission Template

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Technology Appraisals. Patient Access Scheme Submission Template NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Technology Appraisals Patient Access Scheme Submission Template Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line

More information

Managing Immunizations

Managing Immunizations Managing Immunizations In this chapter: Viewing Immunization Information Entering Immunizations Editing Immunizations Entering a Lead Test Action Editing a Lead Test Action Entering Opt-Out Immunizations

More information

AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd.

AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd. PharmaSUG 2016 - Paper IB11 AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd., Pune, India ABSTRACT Adverse event (AE) summary tables

More information

The Third-Party Reimbursement Process for Orthotics

The Third-Party Reimbursement Process for Orthotics The Third-Party Reimbursement Process for Orthotics When the foot hits the ground, everything changes. We know that over 90% of the population suffers with overpronation of their feet. Implementing Foot

More information

CONSENT FORM. The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith

CONSENT FORM. The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith CONSENT FORM The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith Queen Elizabeth Hospital Queen Elizabeth Hospital 60 Riverside Drive 60

More information

Collapsing Longitudinal Data Across Related Events and Imputing Endpoints

Collapsing Longitudinal Data Across Related Events and Imputing Endpoints Collapsing Longitudinal Data Across Related Events and Imputing Endpoints James Joseph, INC Research, King of Prussia, PA INTRODUCTION When attempting to answer a research question, the best study design

More information

User Guide for Classification of Diabetes: A search tool for identifying miscoded, misclassified or misdiagnosed patients

User Guide for Classification of Diabetes: A search tool for identifying miscoded, misclassified or misdiagnosed patients User Guide for Classification of Diabetes: A search tool for identifying miscoded, misclassified or misdiagnosed patients For use with isoft Premiere Synergy Produced by André Ring 1 Table of Contents

More information

ClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT)

ClinicalTrials.gov Basic Results Data Element Definitions (DRAFT) ClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT) January 9, 2009 * Required by ClinicalTrials.gov [*] Conditionally required by ClinicalTrials.gov (FDAAA) May be required to comply with

More information

Appendix B. Nodulus Observer XT Instructional Guide. 1. Setting up your project p. 2. a. Observation p. 2. b. Subjects, behaviors and coding p.

Appendix B. Nodulus Observer XT Instructional Guide. 1. Setting up your project p. 2. a. Observation p. 2. b. Subjects, behaviors and coding p. 1 Appendix B Nodulus Observer XT Instructional Guide Sections: 1. Setting up your project p. 2 a. Observation p. 2 b. Subjects, behaviors and coding p. 3 c. Independent variables p. 4 2. Carry out an observation

More information

Computer Science 101 Project 2: Predator Prey Model

Computer Science 101 Project 2: Predator Prey Model Computer Science 101 Project 2: Predator Prey Model Real-life situations usually are complicated and difficult to model exactly because of the large number of variables present in real systems. Computer

More information

The Hospital Anxiety and Depression Scale Guidance and Information

The Hospital Anxiety and Depression Scale Guidance and Information The Hospital Anxiety and Depression Scale Guidance and Information About Testwise Testwise is the powerful online testing platform developed by GL Assessment to host its digital tests. Many of GL Assessment

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A

More information

Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies

Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies T07-2008 Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies Daojun Mo 1, Xia Li 2 and Alan Zimmermann 1 1 Eli Lilly and Company, Indianapolis, IN 2 inventiv Clinical

More information

Documenting Patient Immunization. Ontario 2018/19

Documenting Patient Immunization. Ontario 2018/19 Documenting Patient Immunization Ontario 2018/19 Table of Contents Documenting Patient Immunization Ontario...3 Immunization Module Features...4 Configuration...5 Marketing Message Setup...6 Paper Mode...9

More information

Methodology for Non-Randomized Clinical Trials: Propensity Score Analysis Dan Conroy, Ph.D., inventiv Health, Burlington, MA

Methodology for Non-Randomized Clinical Trials: Propensity Score Analysis Dan Conroy, Ph.D., inventiv Health, Burlington, MA PharmaSUG 2014 - Paper SP08 Methodology for Non-Randomized Clinical Trials: Propensity Score Analysis Dan Conroy, Ph.D., inventiv Health, Burlington, MA ABSTRACT Randomized clinical trials serve as the

More information

Programmatic Challenges of Dose Tapering Using SAS

Programmatic Challenges of Dose Tapering Using SAS ABSTRACT: Paper 2036-2014 Programmatic Challenges of Dose Tapering Using SAS Iuliana Barbalau, Santen Inc., Emeryville, CA Chen Shi, Santen Inc., Emeryville, CA Yang Yang, Santen Inc., Emeryville, CA In

More information

ProScript User Guide. Pharmacy Access Medicines Manager

ProScript User Guide. Pharmacy Access Medicines Manager User Guide Pharmacy Access Medicines Manager Version 3.0.0 Release Date 01/03/2014 Last Reviewed 11/04/2014 Author Rx Systems Service Desk (T): 01923 474 600 Service Desk (E): servicedesk@rxsystems.co.uk

More information

MedsCheck Reviews. Ontario

MedsCheck Reviews. Ontario MedsCheck Reviews Ontario Contents Configuration... 1 Configuring Electronic Signatures... 1 Configuring Electronic MedsCheck Reviews... 2 Creating an ODB MedsCheck Consent Record... 3 Electronic MedsCheck

More information

A SAS sy Study of ediary Data

A SAS sy Study of ediary Data A SAS sy Study of ediary Data ABSTRACT PharmaSUG 2017 - Paper BB14 A SAS sy Study of ediary Data Amie Bissonett, inventiv Health Clinical, Minneapolis, MN Many sponsors are using electronic diaries (ediaries)

More information

To open a CMA file > Download and Save file Start CMA Open file from within CMA

To open a CMA file > Download and Save file Start CMA Open file from within CMA Example name Effect size Analysis type Level Tamiflu Hospitalized Risk ratio Basic Basic Synopsis The US government has spent 1.4 billion dollars to stockpile Tamiflu, in anticipation of a possible flu

More information

Stata: Merge and append Topics: Merging datasets, appending datasets - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1. Terms There are several situations when working with

More information

PBSI-EHR Off the Charts!

PBSI-EHR Off the Charts! PBSI-EHR Off the Charts! Enhancement Release 3.2.1 TABLE OF CONTENTS Description of enhancement change Page Encounter 2 Patient Chart 3 Meds/Allergies/Problems 4 Faxing 4 ICD 10 Posting Overview 5 Master

More information

Documenting Patient Immunization. New Brunswick 2018/19

Documenting Patient Immunization. New Brunswick 2018/19 Documenting Patient Immunization New Brunswick 2018/19 Table of Contents Documenting Patient Immunization New Brunswick...3 Immunization Module Features...4 Configuration...5 Marketing Message Setup...6

More information

The Hill s Healthy Weight Protocol User Guide. Effective

The Hill s Healthy Weight Protocol User Guide. Effective The Hill s Healthy Weight Protocol User Guide Effective 9.5.2012 1 Welcome! Thank you for participating in the Hill s Healthy Weight Protocol in-clinic pilot. We hope and expect that you find this new

More information

A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial

A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial Christoph Gerlinger * and Ursula Franke ** * Laboratoires Fournier S.C.A. and ** biodat

More information

Lead the Way with Advanced Care Management. Workbook

Lead the Way with Advanced Care Management. Workbook Lead the Way with Advanced Care Management Workbook TPCA Training 10.2018 Section 1: Using i2itracks for Chronic Disease Management Chronic Disease Tracking in 2018 Disease Management Definition A system

More information

Consultation on publication of new cancer waiting times statistics Summary Feedback Report

Consultation on publication of new cancer waiting times statistics Summary Feedback Report Consultation on publication of new cancer waiting times statistics Summary Feedback Report Information Services Division (ISD) NHS National Services Scotland March 2010 An electronic version of this document

More information

MULTIPLE LINEAR REGRESSION 24.1 INTRODUCTION AND OBJECTIVES OBJECTIVES

MULTIPLE LINEAR REGRESSION 24.1 INTRODUCTION AND OBJECTIVES OBJECTIVES 24 MULTIPLE LINEAR REGRESSION 24.1 INTRODUCTION AND OBJECTIVES In the previous chapter, simple linear regression was used when you have one independent variable and one dependent variable. This chapter

More information

v Feature Stamping SMS 13.0 Tutorial Prerequisites Requirements Map Module Mesh Module Scatter Module Time minutes

v Feature Stamping SMS 13.0 Tutorial Prerequisites Requirements Map Module Mesh Module Scatter Module Time minutes v. 13.0 SMS 13.0 Tutorial Objectives Learn how to use conceptual modeling techniques to create numerical models which incorporate flow control structures into existing bathymetry. The flow control structures

More information

Student Minds Turl Street, Oxford, OX1 3DH

Student Minds Turl Street, Oxford, OX1 3DH Who are we? Student Minds is a national charity working to encourage peer support for student mental health. We encourage students to have the confidence to talk and to listen. We aim to bring people together

More information

Table of Contents Foreword 9 Stay Informed 9 Introduction to Visual Steps 10 What You Will Need 10 Basic Knowledge 11 How to Use This Book

Table of Contents Foreword 9 Stay Informed 9 Introduction to Visual Steps 10 What You Will Need 10 Basic Knowledge 11 How to Use This Book Table of Contents Foreword... 9 Stay Informed... 9 Introduction to Visual Steps... 10 What You Will Need... 10 Basic Knowledge... 11 How to Use This Book... 11 The Screenshots... 12 The Website and Supplementary

More information

Discover the birth control you ve been looking for. Highly reliable. Virtually hassle-free. Totally hormone-free.

Discover the birth control you ve been looking for. Highly reliable. Virtually hassle-free. Totally hormone-free. Discover the birth control you ve been looking for Highly reliable. Virtually hassle-free. Totally hormone-free. Over 70 million women worldwide use a nonhormonal IUC like ParaGard. Millions of women with

More information

Imputing Dose Levels for Adverse Events

Imputing Dose Levels for Adverse Events Paper HO03 Imputing Dose Levels for Adverse Events John R Gerlach & Igor Kolodezh CSG Inc., Raleigh, NC USA ABSTRACT Besides the standard reporting of adverse events in clinical trials, there is a growing

More information

MB6810B-Regional Per-Dose Funding Report Report User Guide Modified: Document Version:

MB6810B-Regional Per-Dose Funding Report Report User Guide Modified: Document Version: Manitoba Panorama MB6810B-Regional Per-Dose Funding Report Report User Guide Modified: 2016-01-06 Manitoba ehealth Document Version: 0.05 Document Status: Final January 6, 2016 Document Author: Manitoba

More information

C H C S TAT E I N F L U E N Z A VA C C I N E R E Q U I R E M E N T S T R A I N I N G F O R C O M M U N I T Y P R O V I D E R S

C H C S TAT E I N F L U E N Z A VA C C I N E R E Q U I R E M E N T S T R A I N I N G F O R C O M M U N I T Y P R O V I D E R S 2017-2 0 1 8 C H C S TAT E I N F L U E N Z A VA C C I N E R E Q U I R E M E N T S T R A I N I N G F O R C O M M U N I T Y P R O V I D E R S C O R O N A D O R O O M Nancy Knickerbocker State Flu Vaccine

More information

Nancy Knickerbocker State Flu Vaccine Coordinator County of San Diego Immunization Program

Nancy Knickerbocker State Flu Vaccine Coordinator County of San Diego Immunization Program 2017-2 0 1 8 S TAT E I N F L U E N Z A VA C C I N E D O C U M E N TAT I O N REQUIREMENTS F O R P U B L I C H E A LT H C E N T E R S C O R O N A D O R O O M Nancy Knickerbocker State Flu Vaccine Coordinator

More information

PedCath IMPACT User s Guide

PedCath IMPACT User s Guide PedCath IMPACT User s Guide Contents Overview... 3 IMPACT Overview... 3 PedCath IMPACT Registry Module... 3 More on Work Flow... 4 Case Complete Checkoff... 4 PedCath Cath Report/IMPACT Shared Data...

More information

Dementia Direct Enhanced Service

Dementia Direct Enhanced Service Vision 3 Dementia Direct Enhanced Service England Outcomes Manager Copyright INPS Ltd 2015 The Bread Factory, 1A Broughton Street, Battersea, London, SW8 3QJ T: +44 (0) 207 501700 F:+44 (0) 207 5017100

More information

MedDRA Overview A Standardized Terminology

MedDRA Overview A Standardized Terminology MedDRA Overview A Standardized Terminology Patrick Revelle Director, MedDRA MSSO 6 May 2010 MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers and Associations

More information

Search for studies: ClinicalTrials.gov Identifier: NCT

Search for studies: ClinicalTrials.gov Identifier: NCT ClinicalTrials.gov A service of the U.S. National Institutes of Health Search for studies: Example. "Heart attack" AND "Los Angeles" Advanced Search Help Studies by Topic Glossary Find Studies About Clinical

More information

Content Part 2 Users manual... 4

Content Part 2 Users manual... 4 Content Part 2 Users manual... 4 Introduction. What is Kleos... 4 Case management... 5 Identity management... 9 Document management... 11 Document generation... 15 e-mail management... 15 Installation

More information

Data Management System (DMS) User Guide

Data Management System (DMS) User Guide Data Management System (DMS) User Guide Eversense and the Eversense logo are trademarks of Senseonics, Incorporated. Other brands and their products are trademarks or registered trademarks of their respective

More information

JEFIT ios Manual Version 1.0 USER MANUAL. JEFIT Workout App Version 1.0 ios Device

JEFIT ios Manual Version 1.0 USER MANUAL. JEFIT Workout App Version 1.0 ios Device USER MANUAL JEFIT Workout App Version 1.0 ios Device Jefit, Inc Copyright 2010-2011 All Rights Reserved http://www.jefit.com 1 Table Of Contents 1.) WELCOME - 5-2.) INSTALLATION - 6-2.1 Downloading from

More information

BlueBayCT - Warfarin User Guide

BlueBayCT - Warfarin User Guide BlueBayCT - Warfarin User Guide December 2012 Help Desk 0845 5211241 Contents Getting Started... 1 Before you start... 1 About this guide... 1 Conventions... 1 Notes... 1 Warfarin Management... 2 New INR/Warfarin

More information

Statistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue

Statistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue STATISTICAL ANALYSIS PLAN FOR PROTOCOL RH01649 A Study to Assess Efficacy over Placebo and Speed of Onset of Pain Relief of New Panadol Extra as Compared to Ibuprofen in Episodic Tension Headache BIOSTATISTICS

More information

SAMPLING ERROI~ IN THE INTEGRATED sysrem FOR SURVEY ANALYSIS (ISSA)

SAMPLING ERROI~ IN THE INTEGRATED sysrem FOR SURVEY ANALYSIS (ISSA) SAMPLING ERROI~ IN THE INTEGRATED sysrem FOR SURVEY ANALYSIS (ISSA) Guillermo Rojas, Alfredo Aliaga, Macro International 8850 Stanford Boulevard Suite 4000, Columbia, MD 21045 I-INTRODUCTION. This paper

More information

mehealth for ADHD Parent Manual

mehealth for ADHD Parent Manual mehealth for ADHD adhd.mehealthom.com mehealth for ADHD Parent Manual al Version 1.0 Revised 11/05/2008 mehealth for ADHD is a team-oriented approach where parents and teachers assist healthcare providers

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

HEALTH MANAGEMENT SYSTEM NUTRITION MODULE TABLE OF CONTENTS

HEALTH MANAGEMENT SYSTEM NUTRITION MODULE TABLE OF CONTENTS BIO ANALOGICS HEALTH MANAGEMENT SYSTEM NUTRITION MODULE TABLE OF CONTENTS 1.0 Program Installation 2.0 Installing the Nutrition Module 3.0 Setup Nutrition Recommendation 3.1 Daily Food Distribution 3.2

More information

Integrated ADSL. PhUSE Nate Freimark/Thomas Clinch Theorem Clinical Research

Integrated ADSL. PhUSE Nate Freimark/Thomas Clinch Theorem Clinical Research Integrated ADSL PhUSE 2012-10-17 Nate Freimark/Thomas Clinch Theorem Clinical Research ADSL - Not Without Challenges Where to Begin Source Data One ADSL or Two Number of Records per Subject Update or Create

More information

Clay Tablet Connector for hybris. User Guide. Version 1.5.0

Clay Tablet Connector for hybris. User Guide. Version 1.5.0 Clay Tablet Connector for hybris User Guide Version 1.5.0 August 4, 2016 Copyright Copyright 2005-2016 Clay Tablet Technologies Inc. All rights reserved. All rights reserved. This document and its content

More information

To open a CMA file > Download and Save file Start CMA Open file from within CMA

To open a CMA file > Download and Save file Start CMA Open file from within CMA Example name Effect size Analysis type Level Tamiflu Symptom relief Mean difference (Hours to relief) Basic Basic Reference Cochrane Figure 4 Synopsis We have a series of studies that evaluated the effect

More information

You can use this app to build a causal Bayesian network and experiment with inferences. We hope you ll find it interesting and helpful.

You can use this app to build a causal Bayesian network and experiment with inferences. We hope you ll find it interesting and helpful. icausalbayes USER MANUAL INTRODUCTION You can use this app to build a causal Bayesian network and experiment with inferences. We hope you ll find it interesting and helpful. We expect most of our users

More information

One-Way Independent ANOVA

One-Way Independent ANOVA One-Way Independent ANOVA Analysis of Variance (ANOVA) is a common and robust statistical test that you can use to compare the mean scores collected from different conditions or groups in an experiment.

More information

Wellness Recovery Action Planning (WRAP) WRAP is designed and managed by you and is designed to

Wellness Recovery Action Planning (WRAP) WRAP is designed and managed by you and is designed to Wellness Recovery Action Planning (WRAP) WRAP is designed and managed by you and is designed to Decrease and prevent intrusive or troubling feelings and behaviours Increase personal empowerment Improve

More information

CaseBuilder - Quick Reference Guide

CaseBuilder - Quick Reference Guide ADP UNEMPLOYMENT COMPENSATION MANAGEMENT CaseBuilder - Quick Reference Guide After signing into CaseBuilder, the first screen the user will see is called the Dashboard. The user can then navigate to any

More information

NYSIIS. Immunization Evaluator and Manage Schedule Manual. October 16, Release 1.0

NYSIIS. Immunization Evaluator and Manage Schedule Manual. October 16, Release 1.0 NYSIIS Immunization Evaluator and Manage Schedule Manual October 16, 2007 Release 1.0 Revision History Release Modifications Author Revision Date 1.0 Initial Draft R Savage 10/16/2007 INTRODUCTION: 1 BUILDING

More information

iappeals Screens for the final PSA (May 24) 5

iappeals Screens for the final PSA (May 24) 5 iappeals Screens for the final PSA (May 24) 5 Welcome! This is the starting point to request a review of our medical decision about your eligibility for disability benefits. There are two parts to this

More information

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study

More information

Knowledge is Power: The Basics of SAS Proc Power

Knowledge is Power: The Basics of SAS Proc Power ABSTRACT Knowledge is Power: The Basics of SAS Proc Power Elaina Gates, California Polytechnic State University, San Luis Obispo There are many statistics applications where it is important to understand

More information

GST: Step by step Build Diary page

GST: Step by step Build Diary page GST: At A Glance The home page has a brief overview of the GST app. Navigate through the app using either the buttons on the left side of the screen, or the forward/back arrows at the bottom right. There

More information

OECD QSAR Toolbox v.4.2. An example illustrating RAAF scenario 6 and related assessment elements

OECD QSAR Toolbox v.4.2. An example illustrating RAAF scenario 6 and related assessment elements OECD QSAR Toolbox v.4.2 An example illustrating RAAF scenario 6 and related assessment elements Outlook Background Objectives Specific Aims Read Across Assessment Framework (RAAF) The exercise Workflow

More information

Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials

Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials Paper PO05 Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials Ping Liu ABSTRACT In any phase of clinical trials, dates are very critical throughout the entire trial. However,

More information

Blue Distinction Centers for Fertility Care 2018 Provider Survey

Blue Distinction Centers for Fertility Care 2018 Provider Survey Blue Distinction Centers for Fertility Care 2018 Provider Survey Printed version of this document is for reference purposes only. A completed Provider Survey must be submitted via the online web application

More information

BASE 24-HOUR URINE COLLECTION LITHOLINK CORE LAB

BASE 24-HOUR URINE COLLECTION LITHOLINK CORE LAB CHAPTER 34. BASE 24-HOUR URINE COLLECTION LITHOLINK CORE LAB 34.1 Background Participants who are enrolled in the CKD BASE Study will collect urine over a 24-hour period at B0, W12 and W28. A 50 ml tube

More information

PharmaSUG Paper QT38

PharmaSUG Paper QT38 PharmaSUG 2015 - Paper QT38 Statistical Review and Validation of Patient Narratives Indrani Sarkar, inventiv Health Clinical, Indiana, USA Bradford J. Danner, Sarah Cannon Research Institute, Tennessee,

More information

Tips for Youth Group Leaders

Tips for Youth Group Leaders OVERWHELMED Sometimes youth on the Autism Spectrum become so over-whelmed they are unable to function Most situations can be avoided by asking the youth to gauge their own comfort level Because the body

More information

Intro to SPSS. Using SPSS through WebFAS

Intro to SPSS. Using SPSS through WebFAS Intro to SPSS Using SPSS through WebFAS http://www.yorku.ca/computing/students/labs/webfas/ Try it early (make sure it works from your computer) If you need help contact UIT Client Services Voice: 416-736-5800

More information

Chapter 1: Managing workbooks

Chapter 1: Managing workbooks Chapter 1: Managing workbooks Module A: Managing worksheets You use the Insert tab on the ribbon to insert new worksheets. True or False? Which of the following are options for moving or copying a worksheet?

More information

[HEALTH MAINTENANCE AND INVITATIONS/REMINDERS] June 2, 2014

[HEALTH MAINTENANCE AND INVITATIONS/REMINDERS] June 2, 2014 Health Maintenance tab is located on the left side menu. Health Maintenance will assist with Meaningful Use, Stage 2 objectives. Meaningful Use, objective #6 states the following: Use clinical support

More information

Using the CFS Infrastructure

Using the CFS Infrastructure CHAPTER 13 The Cisco MDS SAN-OS software uses the Cisco Fabric Services (CFS) infrastructure to enable efficient database distribution and to foster device flexibility. It simplifies SAN provisioning by

More information

HEALTH MANAGEMENT SYSTEM MEDICAL RISK APPRAISAL MODULE TABLE OF CONTENTS

HEALTH MANAGEMENT SYSTEM MEDICAL RISK APPRAISAL MODULE TABLE OF CONTENTS BIO ANALOGICS HEALTH MANAGEMENT SYSTEM MEDICAL RISK APPRAISAL MODULE TABLE OF CONTENTS 1.0 Program Module Installation 2.0 MRA Overview 2.1 Auto Advance 2.2 Status bar 2.3 Preview 2.4 More Information

More information

Known Issue Summary Topic Found in Version

Known Issue Summary Topic Found in Version Advanced Audit Audit KI90525 Messaging Service Log files in the C:\NextGen\Services\.NGPr od.auditmessaging\logs are generate logs extremely fast. When opening the log files it is filled

More information

Effective Case Presentations

Effective Case Presentations Effective Case Presentations Alan Lefor MD MPH Department of Surgery Jichi Medical University 4 4 Alan Lefor 1. History The complete medical history always should have six parts It begins with the Chief

More information

Instructor Guide to EHR Go

Instructor Guide to EHR Go Instructor Guide to EHR Go Introduction... 1 Quick Facts... 1 Creating your Account... 1 Logging in to EHR Go... 5 Adding Faculty Users to EHR Go... 6 Adding Student Users to EHR Go... 8 Library... 9 Patients

More information

Unit 1: Introduction to the Operating System, Computer Systems, and Networks 1.1 Define terminology Prepare a list of terms with definitions

Unit 1: Introduction to the Operating System, Computer Systems, and Networks 1.1 Define terminology Prepare a list of terms with definitions AR Computer Applications I Correlated to Benchmark Microsoft Office 2010 (492490) Unit 1: Introduction to the Operating System, Computer Systems, and Networks 1.1 Define terminology 1.1.1 Prepare a list

More information

Graph Display of Patient Profile Using SAS

Graph Display of Patient Profile Using SAS PharmaSUG 2018 - Paper DV-17 Graph Display of Patient Profile Using SAS Yanwei Han, Seqirus USA Inc., Cambridge, MA Hongyu Liu, Seqirus USA Inc., Cambridge, MA ABSTRACT We usually create patient profile

More information

Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro

Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro SESUG 2016 Paper CC-160 Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro Lifang Zhang, Department of Biostatistics and Epidemiology, Augusta University ABSTRACT SAS software

More information

Estimating national adult prevalence of HIV-1 in Generalized Epidemics

Estimating national adult prevalence of HIV-1 in Generalized Epidemics Estimating national adult prevalence of HIV-1 in Generalized Epidemics You are now ready to begin using EPP to generate HIV prevalence estimates for use in the Spectrum program. Introduction REMEMBER The

More information

Using Lertap 5 in a Parallel-Forms Reliability Study

Using Lertap 5 in a Parallel-Forms Reliability Study Lertap 5 documents series. Using Lertap 5 in a Parallel-Forms Reliability Study Larry R Nelson Last updated: 16 July 2003. (Click here to branch to www.lertap.curtin.edu.au.) This page has been published

More information

Charts Worksheet using Excel Obesity Can a New Drug Help?

Charts Worksheet using Excel Obesity Can a New Drug Help? Worksheet using Excel 2000 Obesity Can a New Drug Help? Introduction Obesity is known to be a major health risk. The data here arise from a study which aimed to investigate whether or not a new drug, used

More information

Defect Removal Metrics. SE 350 Software Process & Product Quality 1

Defect Removal Metrics. SE 350 Software Process & Product Quality 1 Defect Removal Metrics 1 Objectives Understand some basic defect metrics and the concepts behind them Defect density metrics Defect detection and removal effectiveness etc. Look at the uses and limitations

More information

iswimmanager User s Manual Training Plan

iswimmanager User s Manual Training Plan iswimmanager User s Manual Training Plan Content Training Plan Creating a training plan entries - wheels Setting multiply times in the set Making training block out of multiple sets Writing favorite sets

More information

General Kcal Count Information

General Kcal Count Information KCAL COUNTS General Kcal Count Information There are 2 kinds of Kcal Counts: E8 and non-e8. E8 have slips of paper that they write on Non E8 have envelopes that they use E8 KCAL COUNTS Non-E8 KCAL COUNTS

More information

Guidance on Base Fair Balance Level Selection and Placement (HCP Advertising)

Guidance on Base Fair Balance Level Selection and Placement (HCP Advertising) Guidance on Base Fair Balance Level Selection and Placement (HCP Advertising) June 2013 Preamble: In alignment with section 9.1 of the Food and Drugs Act, the PAAB code sections 2.1, 2.4, and 3.5 require

More information

icap Monitor User Manual EEG Enterprises, Inc. 586 Main Street Farmingdale, New York TEL: (516) FAX: (516)

icap Monitor User Manual EEG Enterprises, Inc. 586 Main Street Farmingdale, New York TEL: (516) FAX: (516) icap Monitor User Manual EEG Enterprises, Inc. 586 Main Street Farmingdale, New York 11735 TEL: (516) 293-7472 FAX: (516) 293-7417 Copyright 2010-2011 EEG Enterprises, Inc. All rights reserved. The contents

More information

v Feature Stamping SMS 12.0 Tutorial Prerequisites Requirements TABS model Map Module Mesh Module Scatter Module Time minutes

v Feature Stamping SMS 12.0 Tutorial Prerequisites Requirements TABS model Map Module Mesh Module Scatter Module Time minutes v. 12.0 SMS 12.0 Tutorial Objectives In this lesson will teach how to use conceptual modeling techniques to create numerical models that incorporate flow control structures into existing bathymetry. The

More information

Implementing Worst Rank Imputation Using SAS

Implementing Worst Rank Imputation Using SAS Paper SP12 Implementing Worst Rank Imputation Using SAS Qian Wang, Merck Sharp & Dohme (Europe), Inc., Brussels, Belgium Eric Qi, Merck & Company, Inc., Upper Gwynedd, PA ABSTRACT Classic designs of randomized

More information